Affimed: Creating an entirely
new dimension in cancer treatment

We are driven by a steadfast goal to keep cancer from ever derailing patients’ lives.

A one-of-a-kind approach
for revolutionary outcomes

We are revolutionizing cancer treatment by activating
the untapped power of the innate immune system
to eradicate tumors. Our novel and proprietary technology binds NK cells and other innate immune cells directly to tumor cells, allowing for tumor destruction.
This approach is versatile and scalable.

Our approach is differentiated and IP-protected, and has the promise to help patients who have already undergone earlier lines of therapy that proved to be unsuccessful.

Partnerships poised to change
the treatment landscape

We have entered select partnerships with esteemed pharmaceutical companies who share our passion for bringing change to the treatment of cancer.

The power to change patients’ lives

We trust that we can help those who have been
left behind
due to a lack of efficacy or unpredictable
toxicity with traditional therapies. Clinical results already
light the way for patients suffering from multiple types of
cancer. Initial reported data have demonstrated unprecedented ORR in patients who had undergone
earlier lines of therapy that proved to be unsuccessful—including one patient who was about to enter hospice care.


Now is your chance to be part of the next revolution in cancer treatment. Join us.


See our wealth of
clinical literature.


Explore our growing pipeline of
ICE® (innate cell engager)
molecules and combination products.


Join the next revolution
in cancer treatment.

IP=intellectual property; NK=natural killer; ORR=objective response rate.